Bisphosphonate treatment of osteoporosis began with off-label use of etidronate in the 1980s. Alendronate (1995) and rise-dronate (1999). are approved by the US Food and Drug Administration (FDA) for prevention and treatment of post-menopausal osteoporosis and for patients with osteoporosis due to glucocoprticoid treatment. These compounds increase bone mineral density and reduce the risk of fractures of the vertebrae, hips, and other nonvertebral sites. The body of evidence for both safety and efficacy of bisphosphonate treatment of osteoporosis is stronger than for any other agent. Bisphosphonates are safe and well tolerated and represent the agents of choice for most patients with osteoporosis.
KeywordsBone Mineral Density Vertebral Fracture Zoledronic Acid Postmenopausal Osteoporosis Bone Turnover Marker
Unable to display preview. Download preview PDF.
- 11.Schnitzer TJ, Bone HG, Crepaldi G, et al.: Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily for treatment of postmenopausal osteoporosis. Ag/ng Clin Exp Res 2000, 12:1–12.Google Scholar